Novartis in spotlight again over Japan study practices

Save

The leukemia drug was the subject of a multi-center, investigator-initiated joint study begun in 2012, which aimed to gather information on side-effects in chronic myeloid leukemia (CML) patients receiving it or other tyrosine kinase inhibitors.